Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention

NCT05413551 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Tuberculosis Infection
Isoniazid Adverse Reaction

Interventions

DRUG: Low-dose isoniazid
DRUG: Standard dose of isoniazid
DRUG: High-dose isoniazid

Sponsor

Stanford University

Collaborators

[object Object]
[object Object]
[object Object]